New drug ER-100 tested for eye nerve damage: first human trial begins
Symptom relief
Recruiting now
This early-phase study tests whether a single dose of ER-100 is safe for people with two eye nerve conditions: open-angle glaucoma and NAION. About 18 adults will receive the drug and be monitored closely for side effects, eye health, and vision changes over up to 5 years. The go…
Phase: PHASE1 • Sponsor: Life Biosciences Inc. • Aim: Symptom relief
Last updated May 10, 2026 19:47 UTC